Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison China MediTech Ltd.

www.chi-med.com

Latest From Hutchison China MediTech Ltd.

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.

Financing Innovation

China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

China Risk Management

New Funds Extend Chi-Med’s Runway But HK Listing Still Planned

Chi-Med opted to raise modest funds in the US to extend its cash runway ahead of a ‘big year’ but still intends to pursue a larger Hong Kong listing at an appropriate time, its CEO tells Scrip.

Financing Business Strategies

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Chi-Med
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Hong Kong
  • Parent & Subsidiaries
  • Hutchison China MediTech Ltd.
  • Senior Management
  • Christian Hogg, CEO
    Johnny Cheng, CFO
    Weiguo Su, MD, EVP, CSO
  • Contact Info
  • Hutchison China MediTech Ltd.
    Phone: (852) 2128 1188
    48th Fl., Cheung Kong Ctr.
    2 Queen's Rd.
    ,
    Hong Kong
UsernamePublicRestriction

Register